ADMA Biologics Inc Price to Free Cash Flow Ratio 2013-2021 | ADMA

Historical price to free cash flow ratio values for ADMA Biologics Inc (ADMA) since 2013. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ADMA Biologics Inc Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 1.10 0.00
2021-06-30 1.60 $-1.30 0.00
2021-03-31 1.76 $-1.28 0.00
2020-12-31 1.95 $-1.33 0.00
2020-09-30 2.39 $-1.38 0.00
2020-06-30 2.93 $-1.44 0.00
2020-03-31 2.88 $-1.52 0.00
2019-12-31 4.00 $-1.47 0.00
2019-09-30 4.45 $-1.45 0.00
2019-06-30 3.87 $-1.31 0.00
2019-03-31 3.79 $-1.37 0.00
2018-12-31 2.39 $-1.43 0.00
2018-09-30 6.21 $-1.77 0.00
2018-06-30 4.51 $-1.63 0.00
2018-03-31 4.60 $-1.70 0.00
2017-12-31 3.21 $-1.74 0.00
2017-09-30 3.08 $-1.32 0.00
2017-06-30 3.70 $-1.55 0.00
2017-03-31 4.88 $-1.44 0.00
2016-12-31 5.12 $-1.51 0.00
2016-09-30 7.24 $-1.56 0.00
2016-06-30 5.95 $-1.50 0.00
2016-03-31 8.09 $-1.54 0.00
2015-12-31 8.07 $-1.48 0.00
2015-09-30 8.36 $-1.43 0.00
2015-06-30 9.26 $-1.60 0.00
2015-03-31 9.80 $-1.71 0.00
2014-12-31 11.17 $-1.83 0.00
2014-09-30 10.30 $-3.16 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.146B $0.042B
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00